Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 8/20 | 0.54 |
| ▸ | THRA | P10827 | 7/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MMP1 | P03956 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5385626 | 0.94 | THRB (0.49) | THRBTHRAMAPTTP53SMN1; SMN2 | |
| SCHEMBL5398426 | 0.85 | THRB (0.60) | THRBTHRAKDM4ERORCKMT2A | |
| SCHEMBL5382648 | 0.85 | THRB (0.60) | THRBTHRAKDM4ERORCKMT2A | |
| SCHEMBL5385509 | 0.84 | HTR1A (0.39) | THRBTHRAMAPTSMN1; SMN2LMNA | |
| SCHEMBL5385576 | 0.79 | KMT2A (0.41) | MAPTLMNAL3MBTL1HTR1AKDM4E | |
| SCHEMBL5382640 | 0.79 | THRB (0.54) | THRBTHRARORCKMT2A | |
| SCHEMBL5389361 | 0.76 | CYP1B1 (0.41) | MAPTSMN1; SMN2KMT2AMMP1ALDH1A1 | |
| SCHEMBL5385275 | 0.76 | THRA (0.58) | THRBTHRAMAPTLMNAKDM4E | |
| SCHEMBL5385243 | 0.73 | THRA (0.60) | THRBTHRAMAPTSMN1; SMN2LMNA | |
| SCHEMBL5388975 | 0.73 | THRB (0.65) | THRBTHRAMAPTTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199265-B2 | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | KARO BIO AB (SE) | 2007-04-03 | — | — | US | disclosed |
| US-20040097589-A1 | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | KARO BIO AB (SE) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097589-A1 | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | TSHR, THRA, THRB | THRB 3/4885THRA 2/4885MAPT 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.